11th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced the signing of a two agreements wit
9th September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company today announced that inno.N, E&F Healthcare Holdings and existing investor LUPUS Ventures B.V.(LUPUS)
September 2019 - Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced they have been awarded a €5 million loan from RVO’s Innovation Credit budget for clinical trials
25th June 2019 - Glycostem Therapeutics BV today announced they have received GMP license for Glycostem’s proprietary closed production system used to manufacture their lead product, oNKord®, an off-the-shelf,allogeneic Natural Killer(NK) cell therapy.
28th March 2019 - Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment
December 2018 - Glycostem is proud to be commercial partner in the Marie Curie “Mature-NK” programme. The funding for the CAR-NK technology will be well invested.
December 2018 - Together with Enpicom Glycostem has been awarded funding to develop cancer prediction tool for an area without standard therapy.
16th May 2018 - Eurostars, a European joint programme, co-funded from the national budgets of several EUREKA countries and by the European Union through Horizon 2020 has awarded,through a highly-competitive selection process,the Project “A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumour
January 2018 - In August of 2017, Clinical Cancer Research published a report on the positive outcome of Glycostem’s NK-killer cells phase I clinical trial, which was carried out at Radboud University Center in the Netherlands.